Back

Rate ePoster1,863 Views

Poster Session C - Monday Afternoon

Category: IBD

C0363 - The Impact of Bowel Urgency on the Lives of Patients With Ulcerative Colitis in the U.S. and Europe: Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

Monday, October 24, 2022

3:00 PM – 5:00 PM ET

Location: Crown Ballroom

Presenting Author(s)

Marla C. Dubinsky, MD

Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai
New York, New York

Stefan Schreiber, MD¹, Alison Potts Bleakman, MA, PhD², Marla C. Dubinsky, MD³, David T. Rubin, MD, FACG⁴, Toshifumi Hibi, MD, PhD⁵, Remo Panaccione, MD⁶, Theresa Hunter Gibble, PhD², Cem Kayhan, MD², Eoin J. Flynn, ², Christophe Sapin, ², Christian Atkinson, BSc, Mres⁷, Simon Travis, DPhil⁸
¹University Hospital Schleswig-Holstein, Kiel University, Kiel, Schleswig-Holstein, Germany; ²Eli Lilly and Company, Indianapolis, IN; ³Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, NY; ⁴University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL; ⁵Center for Advanced IBD Research and Treatment Kitasato, University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan; ⁶University of Calgary, Calgary, AB, Canada; ⁷Adelphi Real World, Cheshire, England, United Kingdom; ⁸Kennedy Institute, University of Oxford, Oxford, England, United Kingdom

Introduction: The Communicating Needs and Features of IBD Experiences (CONFIDE) study aims to increase understanding of the impact of symptoms, including bowel urgency, on the lives of patients (pts) with moderate to severe Ulcerative Colitis (UC) and Crohn’s disease in the United States (US), Europe (EUR), and Japan. These data focus on pts in the US and EUR.

Methods: Online, quantitative, cross-sectional surveys of pts with moderate to severe UC were conducted in the US and EUR (France, Germany, Italy, Spain, and UK). Data included pt perspectives on their UC symptoms and the impact on their daily lives. Moderate to severe UC was defined based on treatment, steroid use, and/or hospitalization history. Descriptive statistics summarize the data.

Results: 200 US pts (62% male, mean age 40.4 years) and 556 EUR pts (57% male, mean age 38.9 years) completed the survey, with 77% and 54% currently receiving advanced therapies (biologic or novel oral therapy), respectively. The top 3 symptoms currently (past month) experienced by US and EUR pts were diarrhoea (63% and 50%), bowel urgency (47% and 30%) and increased stool frequency (39% and 30%). In past 3 months, pts who have ever experienced bowel urgency or urge incontinence reported bowel urgency (93% US, 89% EUR) and urge incontinence (86% US, 71% EUR) at least once a month (Table). 69% and 65% of all US and EUR pts, respectively, reported wearing a diaper/pad/protection at least once a month in the past 3 months due to fear/anticipation of urge incontinence. For pts receiving advanced therapies, similar patterns were observed. Among both US and EUR pts, the most common UC-related reasons for declining participation in social events were bowel urgency (43% and 30%) and fear of urge incontinence (40% and 32%). Similarly, the most common reasons for declining participation in work/school and sports/physical exercise were bowel urgency and fear of urge incontinence.

Discussion: Bowel urgency, which was the second-most frequently reported symptom, has an extensive impact on the lives of pts with moderate to severe UC. In this younger pt population, including pts receiving advanced therapies, almost two thirds of US and EUR pts reported wearing diapers/pads/protection at least once a month in the past 3 months due to fear/anticipation of urge incontinence. Both US and EUR pts reported bowel urgency and fear of urge incontinence as the top reasons for declining participation in social events, work/school, and sports/physical exercise.

Frequency of bowel urgency

(all patients who have ever experienced bowel urgency)

Frequency

of urge incontinence

(all patients who have ever experienced urge incontinence)

Frequency of diaper/pad/other protection use due to fear/anticipation of urge incontinence

(all patients)

US patients (n=123)

EUR patients

(n=250)

US patients

(n=90)

EUR patients

(n=175)

US patients

(n=200)

EUR patients

(n=556)

At least once a month, n (%)

Less frequently than monthly, n (%)

Not in the last three months, n (%)

114 (93)

7 (6)

2 (2)

222 (89)

19 (8)

9 (4)

77 (86)

5 (6)

8 (9)

124 (71)

25 (14)

26 (15)

137 (69)

15 (8)

48 (24)

361 (65)

60 (11)

135 (24)

* Percentages are rounded and as a result totals may not add up to 100%

Table: Table. Frequency of bowel urgency, urge incontinence and diaper/pad/other protection use over the past 3 months*

Disclosures:

Stefan Schreiber: AbbVie – Consultant, Personal fees. Arena – Consultant, Personal fees. Biogen – Consultant, Personal fees. Bristol-Myers Squibb – Consultant, Personal fees. Celgene – Consultant, Personal fees. Celltrion – Consultant, Personal fees. Eli Lilly and Company – Consultant, Personal fees. Falk – Consultant, Personal fees. Ferring – Consultant, Personal fees. Fresenius – Consultant, Personal fees. Galapagos/Gilead Sciences – Consultant, Personal fees. IMAB – Consultant, Personal fees. Janssen – Consultant, Personal fees. MSD – Consultant, Personal fees. Mylan – Consultant, Personal fees. Pfizer Inc – Consultant, Personal fees. Protagonist – Consultant, Personal fees. Provention Bio – Consultant, Personal fees. Takeda – Consultant, Personal fees. Theravance – Consultant, Personal fees.

Alison Potts Bleakman: Eli Lilly and Company – Employee.

Marla Dubinsky: AbbVie – Consultant. Arena Pharmaceuticals – Consultant. Bristol Myers Squibb – Consultant. Celgene – Consultant. Eli Lilly – Consultant. Galapagos – Consultant. Genetech – Consultant. Gilead Sciences – Consultant. Janssen Pharmaceuticals – Consultant. Pfizer Inc – Consultant. Prometheus Laboratories – Consultant. Takeda – Consultant. Trellus Health – Shareholder. UCB – Consultant.

David Rubin: AbbVie – Consultant. Alimentiv Inc. – Consultant. AltruBio – Consultant. Arena Pharmaceuticals – Consultant. Aslan Pharmaceuticals – Consultant. Athos Therapeutics – Consultant. Bellatrix Pharmaceuticals – Consultant. Boehringer Ingelheim, Ltd. – Consultant. Bristol Myers Squibb – Consultant. Celgene Corp/Syneos – Consultant. ClostraBio – Consultant. Connect BioPharma – Consultant. EcoR1 – Consultant. Genentech/Roche – Consultant. Gilead Sciences – Consultant. Ironwood Pharmaceuticals – Consultant. Iterative Scopes – Consultant. Janssen – Consultant. Kaleido Biosciences – Consultant. Lilly, Eli & Co – Consultant. Materia Prima – Consultant. Pfizer – Consultant. Prometheus Biosciences – Consultant. Reistone Biopharma – Consultant. Seres Therapeutics, Inc – Consultant. Takeda – Consultant, Grant/Research Support. Target RWE – Consultant. Techlab – Consultant. Trellus Health – Consultant.

Toshifumi Hibi: Abbvie GK – Consultant, Grant/Research Support. Activaid – Grant/Research Support. Alfresa Pharma Corporation – Grant/Research Support. Apo Puls Station – Consultant. Bristol-Myaers Squibb – Consultant, Grant/Research Support. Celltrion – Consultant. EA Pharma – Consultant. Eli Lilly and Company – Consultant, Grant/Research Support. Ferring Pharmaceuticals – Grant/Research Support. Gilead Sciences – Consultant, Grant/Research Support. Janssen – Consultant, Grant/Research Support. JMDC Inc – Grant/Research Support. Kyorin – Consultant. Mitsubishi-TanabePharma – Consultant. Mochida Pharmaceutical Co – Grant/Research Support. Nichi-IkoPharmaceutical – Consultant. Nippon Kayaku Co. – Grant/Research Support. Pfizer – Consultant, Grant/Research Support. Takeda Pharmaceutical – Consultant, Grant/Research Support. Zeria Pharmaceutical – Consultant.

Remo Panaccione: Abbott – Consultant. AbbVie – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Alimentiv – Consultant. Amgen – Advisory Committee/Board Member, Consultant. Arena – Advisory Committee/Board Member, Consultant, Speakers Bureau. AstraZeneca – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant. Celgene – Advisory Committee/Board Member, Consultant, Speakers Bureau. Celltrion – Advisory Committee/Board Member, Consultant. Cosmos Pharmaceuticals – Consultant. Eisai – Consultant. Elan – Consultant. Eli Lilly – Advisory Committee/Board Member, Consultant, Speakers Bureau. Ferring – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Galapagos – Advisory Committee/Board Member, Consultant. Genentech – Advisory Committee/Board Member, Consultant. Gilead Sciences – Advisory Committee/Board Member, Consultant, Speakers Bureau. GlaxoSmithKline – Advisory Committee/Board Member, Consultant. Janssen – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Merck – Advisory Committee/Board Member, Consultant, Speakers Bureau. Mylan – Advisory Committee/Board Member, Consultant. Oppilan Pharma – Advisory Committee/Board Member, Consultant. Pandion Pharma – Advisory Committee/Board Member. Pandion Therapeutics – Consultant. Pfizer – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Progenity – Consultant. Protagonist Therapeutics – Consultant. Roche – Consultant, Speakers Bureau. Sandoz – Advisory Committee/Board Member, Consultant, Speakers Bureau. Satisfai Health – Consultant. Schering-Plough – Consultant. Shire – Advisory Committee/Board Member, Consultant, Speakers Bureau. Sublimity Therapeutics – Advisory Committee/Board Member, Consultant. Takeda – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Theravance – Advisory Committee/Board Member, Consultant. UCB – Consultant.

Theresa Hunter Gibble: Eli Lilly and Company – Employee.

Cem Kayhan: Eli Lilly and Company – Employee, Stock-publicly held company(excluding mutual/index funds).

Eoin Flynn: Eli Lilly and Company – Employee, Stock-publicly held company(excluding mutual/index funds).

Christophe Sapin: Eli Lilly and Company – Employee, Stock-publicly held company(excluding mutual/index funds).

Christian Atkinson: Eli Lilly and Company – Consultant.

Simon Travis: Abacus – Consultant. Abbvie – Consultant, Grant/Research Support. Actial – Consultant. ai4gi – Consultant. Alcimed – Consultant. Allergan – Consultant. Amgen – Consultant. Apexian – Consultant. Aptel – Consultant. Arena – Consultant. Asahi – Consultant. Aspen – Consultant. Astellas – Consultant. AstraZeneca – Consultant. Atlantic – Consultant. Barco – Consultant. Biocare – Consultant. Biogen – Consultant. BLPharma – Consultant. BMS – Consultant. Boehringer Ingelheim – Consultant. Buhlmann – Consultant, Grant/Research Support. Calcico – Consultant. Celgene – Consultant, Grant/Research Support. Cellerix – Consultant. Cerimon – Consultant. ChemoCentryx – Consultant. Chiesi – Consultant. Cisbio – Consultant. ComCast – Consultant. Coronado – Consultant. Cosmo – Consultant. Ducentis – Consultant. Dynavax – Consultant. ECCO – Grant/Research Support. Elan – Consultant. Enterome – Consultant. EQrX – Consultant. Equillium – Consultant. Falk – Consultant. Ferring – Consultant. FPRT Bio – Consultant. Galapagos – Consultant. Genentech/Roche – Consultant. Genzyme – Consultant. Gilead – Consultant. Glenmark – Consultant. Grunenthal – Consultant. GSK – Consultant. GW Pharmaceuticals – Consultant. Helmsley Trust – Grant/Research Support. Immunocore – Consultant. Immunometabolism – Consultant. Indigo – Consultant. IOIBD – Grant/Research Support. Janssen – Consultant, Grant/Research Support. Lexicon – Consultant. Lilly – Consultant, Grant/Research Support. Medarex – Consultant. Medtrix – Consultant. Merck – Consultant. Merrimack – Consultant. Mestag – Consultant. Millenium – Consultant. Neovacs – Consultant. Norman Collisson Foundation – Grant/Research Support. Novartis – Consultant. Novo Nordisk – Consultant. NPS-Nycomed – Consultant. Ocera – Consultant. Optima – Consultant. Origin – Consultant. Otsuka – Consultant. P&G – Consultant. Palau – Consultant. Pentax – Consultant. Pfizer – Consultant, Grant/Research Support. Pharmaventure – Consultant. Phesi – Consultant. Phillips – Consultant. Pronota – Consultant. Protagonist – Consultant. Proximagen – Consultant. Resolute – Consultant. Robarts – Consultant. Sandoz – Consultant. Santarus – Consultant. Satisfai – Consultant. Sensyne Health – Consultant. Shire – Consultant. SigmoidPharma – Consultant. Sorriso – Consultant. Souffinez – Consultant. Syndermix – Consultant. Synthon – Consultant. Takeda – Consultant, Grant/Research Support. Theravance – Consultant. Tigenix – Consultant. Tillotts – Consultant. Topivert – Consultant. Trino Therapeutics with Wellcome Trust – Consultant. TxCell – Consultant. UCB Pharma – Consultant, Grant/Research Support. UKIERI – Grant/Research Support. Vertex – Consultant. VHsquared – Consultant. Vifor – Consultant, Grant/Research Support. Warner Chilcott and Zeria – Consultant.